Telomir Pharmaceuticals, Inc. (TELO) - 8-K Summary
Business Context and Reporting Period
Telomir Pharmaceuticals, Inc., an emerging growth company incorporated in Florida, filed this Form 8-K on November 12, 2025. The filing reports a significant preclinical scientific development regarding the Company's lead investigational compound, Telomir-1.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on scientific data and does not contain financial statements or operational metrics.
Material Changes and Scientific Findings
The Company announced new live-cell imaging data demonstrating that Telomir-1 outperforms the FDA-approved gold-standard iron chelator, Deferoxamine (DFO), in reducing intracellular iron.
- Study Method: Human keratinocyte (HaCaT) cells were treated with Telomir-1 or DFO and evaluated using FerroOrange, a fluorescent probe for ferrous iron.
- Results: Telomir-1 produced a strong, dose-dependent reduction of intracellular iron at submicromolar concentrations, showing greater cellular penetration than DFO.
- Comparison: DFO exhibited limited intracellular activity under equivalent conditions.
Outlook, Management Commentary, and Risks
Management emphasizes that these findings support ongoing pre-clinical research into metal-ion balance, oxidative stress, and epigenetic enzyme dynamics. The data suggests Telomir-1's potential to address issues related to accelerated aging, neurodegenerative, metabolic, cardiovascular, and oncologic diseases by modulating reactive iron levels.
Formulation Update: The Company noted that Telomir-1 has been formulated with zinc (Telomir-Zn) to enable controlled intracellular exchange of metal ions, binding excess reactive metals while contributing zinc as a cofactor for antioxidant defense.
Risks: The filing describes preclinical data only. No clinical trial results or regulatory approvals are reported. The efficacy and safety of Telomir-1 in humans remain unproven.
Investor Verification Checklist
- Verify the specific concentration levels of Telomir-1 used in the HaCaT cell study.
- Confirm the timeline for any planned in vivo studies or clinical trials based on this data.
- Review the Company's cash position and burn rate in recent 10-Q or 10-K filings to assess runway for continued preclinical development.
- Investigate the regulatory pathway for Telomir-1 and Telomir-Zn given the lack of current FDA approval.